tiprankstipranks
Moleculin Biotech (MBRX)
NASDAQ:MBRX

Moleculin Biotech (MBRX) Income Statement

1,327 Followers

Moleculin Biotech Income Statement

Last quarter (Q4 2023), Moleculin Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Moleculin Biotech's net income was $-10.27M. See Moleculin Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 12.00K-----
Operating Expense
$ 12.92M$ 29.63M$ 30.64M$ 22.97M$ 19.74M$ 17.52M
Operating Income
$ -12.92M$ -29.63M$ -30.64M$ -22.97M$ -19.74M$ -17.52M
Net Non Operating Interest Income Expense
$ 1.37M$ 1.37M$ 240.00K$ 306.00K$ 13.00K$ 13.00K
Other Income Expense
$ 996.00K$ 996.00K$ -1.38M$ -6.77M$ 2.37M$ 4.08M
Pretax Income
$ -12.55M$ -29.26M$ -29.02M$ -15.89M$ -17.36M$ -13.43M
Tax Provision
---$ -25.00K$ 0.00$ -229.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -13.06M$ -29.77M$ -29.02M$ -15.89M$ -17.36M$ -13.21M
Basic EPS
$ -5.57$ -15.07$ -1.01$ -0.59$ -1.76$ -1.92
Diluted EPS
$ -5.57$ -15.07$ -1.01$ -0.59$ -1.76$ -1.92
Basic Average Shares
$ 60.46M$ 1.98M$ 28.60M$ 26.88M$ 9.85M$ 6.79M
Diluted Average Shares
$ 60.46M$ 1.98M$ 28.60M$ 26.88M$ 9.85M$ 6.79M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 12.92M$ 29.63M$ 30.64M$ 22.97M$ 19.74M$ 17.52M
Net Income From Continuing And Discontinued Operation
$ -29.77M$ -29.77M$ -29.02M$ -15.89M$ -17.36M$ -13.21M
Normalized Income
$ -12.43M$ -23.11M$ -20.53M-$ -19.70M$ -17.20M
Interest Expense
------
EBIT
$ -12.05M$ -29.63M$ -29.27M$ -16.20M$ -19.74M$ -17.52M
EBITDA
$ -5.98M$ -29.50M$ -29.14M$ -16.04M$ -19.54M$ -17.32M
Currency in USD

Moleculin Biotech Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis